Primary Antibodies
Secondary Antibodies
Proteins & Peptides
ELISA Kits
About Us
Contact Us
Antibodies.com Logo Antibodies.com Logo
Sign In/Register
0
ISO 9001:2015 Certified
Live Customer Support
4.5/5 on Trustpilot
100% Quality Guarantee

Trevogrumab Biosimilar - Anti-Myostatin Antibody (PE) (A333793)

Antibodies.com Image Placeholder - Discover more for less
Antibodies.com Image Placeholder - Discover more for less
This product is discontinued

Trevogrumab Biosimilar - Anti-Myostatin Antibody (PE) (A333793) has been discontinued and is no longer available.

View all Myostatin Antibodies.

  • Specifications

Name
Trevogrumab Biosimilar - Anti-Myostatin Antibody (PE)
Description
Recombinant human monoclonal antibody to Myostatin (PE).
Applications
Flow Cytometry
Dilutions
Flow Cytometry: 1:100
Reactivity
Human
Host
Human
Clonality
Monoclonal
Isotype
IgG4
Conjugate

PE

Excitation: 565nm, Emission: 578nm

Purification
Affinity chromatography.
Concentration
Lot Specific
Product Form
Liquid
Formulation
Supplied in Phosphate Buffered Saline with 0.05% Proclin 300 and 1% BSA.
Storage
Store at 4°C. Do not freeze!
Synonyms
GDF-8, GDF8, Growth/differentiation factor 8, MSTN
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.

Alternative products to Trevogrumab Biosimilar - Anti-Myostatin Antibody (PE) (A333793)

Antibodies.com Image Placeholder - Discover more for less
A333792
Apitegromab Biosimilar - Anti-Myostatin Antibody (PE)
Recombinant human monoclonal antibody to Myostatin (PE) for Flow Cytometry.
Antibodies.com Image Placeholder - Discover more for less
A333792
Apitegromab Biosimilar - Anti-Myostatin Antibody (PE)
Recombinant human monoclonal antibody to Myostatin (PE) for Flow Cytometry.

Proteins predicted to interact with Myostatin

Predicted protein interactions based upon String database. Revelancy score correlates with probability of interaction.
99.9% Relevancy Score
99.9% Relevancy Score
99.9% Relevancy Score
99.7% Relevancy Score
99.5% Relevancy Score
91.5% Relevancy Score
88.7% Relevancy Score
87.7% Relevancy Score
87.4% Relevancy Score